I agree. I emailed the FDA last week and put in my two cents. And emailed AP yesterday after a news story called Anatabloc "sketchy." Good news is new management seems sharp and the new guy with all the FDA experience can't hurt.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.